Good Ol' Metformin Shines Again: Study Says It Reduces Pancreatic Cancer Risk in Type 2s by 62 Percent


Aug 5, 2009

Metformin is one of the oldest and most tried-and-true diabetes treatments around, but apparently it has a new talent. According to research from the M.D. Anderson Cancer Center at the University of Texas, good ol' metformin reduces a type 2 person's risk of pancreatic cancer by 62 percent.  

This is great news for people with diabetes, whose risk of developing pancreatic cancer is higher than that of people without diabetes. Lowering that risk is definitely worthwhile, especially because pancreatic cancer is the most virulent form of cancer and has the lowest survival rate: Only 20 percent of people diagnosed with it live past the one-year mark, and only 5 percent reach the five-year mark.

Metformin was first marketed in France in 1979, but was not approved by the FDA for sale in the United States until 1994.  The following year, Bristol-Meyers Squibb introduced it under the brand name Glucophage. Today metformin is available as a generic, and doctors write approximately 35 million prescriptions for it each year in this country.

Metformin is frequently described as a "first-line" drug because it is the drug most often prescribed for newly diagnosed type 2 patients, usually when they are overweight and demonstrate insulin resistance. It works by increasing cellular sensitivity to insulin  while simultaneously decreasing the amount of insulin circulating in the body.

Those effects are crucial because some scientists believe that insulin may actually promote cancer cell growth. By lowering insulin levels, metformin reduces the risk that the hormone will abet the development of cancerous growths.

In their four-year study, conducted from 2004 to 2008, the researchers studied 1,838 participants, including 973 patients with pancreatic adenocarcinoma (a malignant gland tumor). People with diabetes were divided into four groups according to the type of anti-diabetes drug they were taking: insulin or insulin secretagogues; metformin; TZDs (thiazolidinediones); or "other" common diabetes drugs.

Type 2s who took metformin, either alone or in combination with other drugs, experienced a 62 percent reduction in their risk of developing pancreatic cancer compared to those who never used the drug. Interestingly, common diabetic risk factors, such as smoking, obesity, and poor glycemic control, did not significantly affect the overall risk reduction experienced by metformin users.

The study also found, however, that people with diabetes who had previously taken insulin or insulin secretagogues ran, respectively, a 4.99-fold and a 2.52-fold increased risk for pancreatic cancer compared to people who had never used insulin.

The Texas researchers' interest in metformin's cancer-preventive properties was inspired by an animal study showing that the drug prevented pancreatic tumors. The researchers were also encouraged by several epidemiological studies of people with diabetes showing that metformin reduced the risk of any kind of cancer. Their findings, which will have to be confirmed by a much larger research sample, could lead to the use of metformin as a "chemopreventive," an agent employed to thwart the onset of cancer.

Results of the study, which was led by Prof. Donghui Li, PhD, of the Department of Gastrointestinal Medical Oncology at M.D. Anderson, were published in the August 1 issue of Gastroenterology.        

Click Here To View Or Post Comments

Categories: Community, Diabetes, Diabetes, Insulin, Medications, Metformin, Products, Research, Type 2 Issues

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (2)

You May Also Be Interested In...


Posted by Steve Parker, M.D. on 6 August 2009

To put these issue in perspective . . .
About one in every 75 people in the U.S. will develop pancreatic cancer. That translates to 38,000 new cases yearly. Both type 1 and type 2 diabetics are twice as likely as the general population to develop it.

-Steve Parker, M.D.

Posted by LucienPotvin on 12 August 2009

Isn't the effect here due to the reduction of circulating insulin rather than the drug itself?
Then any method used to reduce insulin would have similar results.
A low Carb Ketogenic diet reduces insulin requirements and lower insulin improves insulin sensitivity. Would that provide the same results as the claim made for Metformin? The low Carb/K diet certainly improves general health and provides a certain measure of rejuvenation.

Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.